Searched for
SYNGENE IPO
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...- Syngene makes strong debut on the bourses, jumps 24%Syngene International, a research arm of biotech major Biocon, made a strong debut on the bourses on Tuesday.
- Syngene International makes stellar debut, ends day up 24% over issue priceIt hit an intraday high of Rs 318.20 over its issue price, before settling the day at Rs 310.40, up 24.16 per cent on the BSE.
- First pharma IPO in 5 years: Syngene’s debut offer subscribed 32 timesThe Rs 550-crore initial public offer of Syngene, a research arm of Biocon, was subscribed 32 times on the final day of the offer
- Syngene IPO gets robust response; issue subscribed 32 timesThe Rs 550 crore IPO of Syngene International was over-subscribed 32.03 times on the last day of the offer today as both retail and institu...
- Syngene IPO over-subscribed on second dayThe IPO got bids for 1,60,79,700 shares against 1,60,00,000 shares on offer, resulting in a subscription of 1.01 (rpt) 1.01 times, accordin...
- Syngene IPO subscribed 32% on Day 1The initial public offering of biotechnology major Biocon's research arm Syngene International was subscribed 32 per cent on the first day ...
- Syngene's valuations are fair, investors need to invest in its growth story: Kiran Mazumdar-ShawIn an interview with ET Now, Kiran Mazumdar-Shaw, CMD, Biocon, talks about the Syngene IPO and the growth prospects involved.
- Top brokers recommend 'subscribe' to Syngene International IPO; here's whyLong-term investors should 'subscribe' to Syngene IPO which opens for subscription today, various brokerages said in a report.
- Management commentary, capex outlook hold the key for Biocon: Mayuresh JoshiIf you look at how the business model has evolved for Biocon, Syngene is the one which is driving the overall profitability for the company...
- Biocon sets Syngene IPO price band at Rs 240-250Biocon plans to raise Rs 550 crore by diluting 11% stake in Syngene through the Initial Public Offer. The proceeds will mostly go into fund...
- Syngene IPO opens July 27; price band at Rs 240-250; Biocon shares end in redBiocon's subsidiary Syngene has set the price band for its forthcoming IPO at Rs 240-250 per share that will open on July 27.
- Plan to list Syngene in August, use IPO proceeds for R&D: Kiran Mazumdar-ShawSyngene International, present in the contract services business, had filed its draft red herring prospectus (DRHP) with Sebi .
- Syngene to be listed by August; IPO proceeds to be used for R&D: Kiran Mazumdar Shaw, BioconKiran Mazumdar Shaw, CMD, Biocon Ltd, tells us about the progress with the Syngene IPO and how the proceeds from the same will be used.
- Syngene gets FIPB nod to raise foreign investment to 44%Syngene, a subsidiary of Biocon, said it has received the Foreign Investment Promotion Board approval to raise foreign investment to 44 per...
- Analysis: Can Syngene IPO Change Biocon's Fortunes?Contributing one-fourth of the consolidated revenues, Syngene has been Biocon's best-performing segment in the last couple of years.
- Biocon surges as company files prospectus for Syngene IPO to raise Rs 600 crore; ends in redBiocon surged over 3% in intraday trade on Thursday after the company filed prospectus for Syngene IPO on Wednesday to raise Rs 600 cr .
- Syngene dragged too far as value proposition; avoid Biocon: Prakash DiwanWhile Syngene has a healthy pipeline of biosimilars, the monetisation of some of the molecules could take up to six years, says Diwan.
- Biocon rallies on plans to list unit Syngene InternationalBiocon gained 2% in intraday trade following reports that the co plans to list its research services business arm Syngene International.
- Biocon to sell up to 25% in Syngene via IPOBiocon will launch an IPO for its fully-owned contract research subsidiary Syngene this financial year.
Load More
